50jili login account

Tribal lands were stolen. What happens when those ancestral territories are returned?SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. ZNTL , a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on December 2, 2024, the Compensation Committee of Zentalis' Board of Directors granted the following equity awards: non-qualified stock options to purchase an aggregate of 3,028,800 shares of the Company's common stock to Julie Eastland, who joined the Company as Chief Executive Officer and President, non-qualified stock options to purchase an aggregate of 712,650 shares of the Company's common stock to Dr. Ingmar Bruns, who joined the Company as Chief Medical Officer, and non-qualified stock options to purchase an aggregate of 753,660 shares of the Company's common stock to five newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.66 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options granted to Ms. Eastland have a 10-year term and will vest over four years in equal monthly installments until the stock options are fully vested. The stock options granted to the other newly hired employees have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employee's continued service to Zentalis on each vesting date. About Zentalis Pharmaceuticals Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The Company's lead product candidate, azenosertib (ZN-c3), is a potentially first-in-class and best-in-class WEE1 inhibitor for advanced solid tumors. Azenosertib is being evaluated as a monotherapy and in combination across multiple clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. As part of its azenosertib clinical development program, the Company is exploring enrichment strategies targeting tumors of high genomic instability, such as Cyclin E1 positive tumors, homologous recombination deficient tumors and tumors with oncogenic driver mutations. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in San Diego. For more information, please visit www.zentalis.com . Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals . ZENTALIS ® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. Contacts: Elizabeth Hickin Vice President, Investor Relations ehickin@zentalis.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

ATLANTA (AP) — Already reeling from their November defeats, Democrats now are grappling with President Joe Biden’s pardoning of his son for federal crimes, with some calling the move misguided and unwise after the party spent years slamming Donald Trump as a threat to democracy who disregarded the law. The president pardoned Hunter Biden late Sunday evening, reversing his previous pledges with a grant of clemency that covers more than a decade of any federal crimes his son might have committed. The 82-year-old president said in a statement that his son’s prosecution on charges of tax evasion and falsifying a federal weapons purchase form were politically motivated. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the proposed offering. UBS Investment Bank is acting as lead manager. A shelf registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) on March 4, 2024, and automatically became effective upon filing. This offering is being made solely by means of a prospectus. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at [email protected] and [email protected] ; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at [email protected] ; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at [email protected] ; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at [email protected] . This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552. Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Revolution Medicines, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding completion, timing and size of the proposed public offering. Such forward-looking statements involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events, and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Revolution Medicines undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to Revolution Medicines' business in general, see the preliminary prospectus supplement related to the proposed public offering and Revolution Medicines' current and future reports filed with the SEC, including Revolution Medicines' Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. CONTACT: Revolution Medicines Investor & Media Contacts: [email protected] ; [email protected]

Shareholders who sued Diana Containerships and Toronto hedge fund Murchinson over Kalani Investments’ backing of the US-listed shipowner have ended the case after eight years. The decision by lead plaintiffs Burcin Ekser, Steven Gerber, and Gianfilippo Mogavero came in response to an order by a US district judge, threatened to throw out the lawsuit after the defeat of similar cases against other shipowners funded by Kalani. The voluntary dismissal filed by the shareholders’ lawyers at Pomerantz effectively puts an end to the class action lawsuit. A legal expert with knowledge of such disputes said any other shareholders who might seek to carry the case forward would face a statute of limitations that would likely prevent them from filing anew. As TradeWinds has reported, investors filed the lawsuit in 2017 alleging that Diana Containerships, led by Simeon Palios at the time and before the company became Performance Shipping, engaged in a manipulative series of transactions with Kalani that pushed down the value of the shares. According to the lawsuits, Diana Containerships issued shares at a discount to Kalani, which then sold them in the market. When the share price fell below the levels required for a US listing, Diana Containerships carried out reverse stock splits. But Diana Containerships and its Murchinson co-defendants had asserted from the start that the transactions had been disclosed to investors. The case was one of three filed in 2017 in the US District Court for the Eastern District of New York over similar Kalani deals with US-listed Greek shipowners. US district judge Brian Cogan presided over the trio of cases, dismissing a lawsuit against George Economou’s DryShips in October of this year and another against Evangelos Pistiolis-led Top Ships in 2019. Earlier this month, he issued an order asking why he should not dismiss the Diana Containerships case in light of the DryShips decision. The shareholders’ lawyers filed the voluntary dismissal rather than answer that question. Murchinson, Kalani and Bistricer are represented in the case by law firm Schulte Roth & Zabel, while Diana Containerships had Fried, Frank, Harris, Shriver & Jacobson on its side.Presidential election outcome sparks concern, fear in local LGBTQ+ community members

Eagles WR DeVonta Smith (hamstring) ruled out vs. RamsElon Musk, the world's richest person and one of Donald Trump's closest allies, met with US lawmakers Thursday on his plans for overseeing radical government spending cuts under the incoming administration. President-elect Trump rewarded the Tesla, X and SpaceX chief for his support during the White House campaign by naming him head of the newly created Department of Government Efficiency, along with another wealthy ally, Vivek Ramaswamy. Although the office, dubbed DOGE, has a purely advisory role, Musk's star power and intense influence in Trump's inner circle bring political clout. As Musk and Ramaswamy strode into the Capitol for meetings with lawmakers, Republican Speaker Mike Johnson touted "a new day in America." "There's an enormous amount of waste, fraud and abuse," he told reporters. "Government is too big, it does too many things, and it does almost nothing well." Musk and Ramaswamy have said they can identify billions of dollars of cuts in spending, sparking questions about whether Republicans will even try to slash politically popular social security programs. Writing in the Wall Street Journal last month, the two businessmen laid out plans for the White House to cut staff, trim government programs and reduce federal regulations, even if it means bypassing Congress, which holds budgetary power. "The entrenched and ever-growing bureaucracy represents an existential threat to our republic, and politicians have abetted it for too long," Musk and Ramaswamy wrote. "We're doing things differently. We are entrepreneurs, not politicians. During Trump's election campaign, Musk vowed to reduce federal spending by $2 trillion. This would represent cutting total US spending by a third, almost certainly meaning devastation of social support programs -- something that has never garnered strong political backing. Musk's emphasis on firing large numbers of government employees, however, echoes Republican talking points about the need to take on an overbearing state and may garner more support. Musk says he is seeking "mass head-count reductions across the federal bureaucracy." Musk suggested banning government employees from working at home as an opening tactic. "Requiring federal employees to come to the office five days a week would result in a wave of voluntary terminations that we welcome." Cuts will also target subsidies to public broadcasters and groups such as Planned Parenthood, which campaigns for abortion access and offers an array of reproductive health services. But DOGE is unlikely, at least initially, to go after welfare programs such as Social Security or health insurance for the poor and seniors, Ramaswamy said in an interview with Axios on Wednesday. Such cuts should be "a policy decision that belongs to the voters" and their representatives in Congress, Ramaswamy said. A reduction in military spending, which climbed to $820 billion in 2023, is also unlikely to be on the table. Musk's new role raises the question of potential conflicts of interest, since he could be issuing policy recommendations that impact directly on his own business empire. Underlining the close connection to DOGE, Musk's favorite cryptocurrency is called Dogecoin. rle/ev/md/sms/mdFutehodo , an abbreviation of the title of the popular drama "Futekisetsu nimo hodo ga aru!" was selected as Japan's top buzzword for 2024, the award's organizer said Monday. The drama, known as "Extremely Inappropriate!" in English and available on Netflix, depicts a physical education teacher who time travels between Japan's Showa Era (1926-1989) and the present Reiwa Era, which began in 2019, and finds his ideas in conflict with modern-day norms. Also among the top 10 buzzwords were "50-50," referring to Shohei Ohtani's achievement of becoming the first player with 50 home runs and 50 steals in a single Major League Baseball season, as well as several terms related to the Paris Olympics. The list also included uragane mondai , in reference to the slush funds scandal that roiled the ruling Liberal Democratic Party; kaiwai , often used by Gen Z on social media for communities tied to a particular fandom; and "Bling-Bang-Bang-Born," a song by Creepy Nuts and the theme song for the anime "Mashle." The chorus phrase became a hot topic in dance videos.

TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Timbercreek Alternatives LP, a subsidiary of Timbercreek Capital, and Aspen Properties today announced the closing of the previously announced acquisition of the 1 Palliser Square Office Building in Calgary, Alberta for the purpose of converting approximately 418,000 square feet of office into 418 residential units and amenities. 1 Palliser Square is a 27-storey, vacant B-class office building centrally located next to the Calgary Tower, with direct access to residential amenities, entertainment and transit. The project is part of the City of Calgary’s Downtown Development Incentive Program designed to transform vacant office space into new rental housing stock. 1 Palliser Office-to-Residential Project Highlights: The acquisition was completed though a joint venture called 1 Palliser Square LP (the “LP”). As part of the acquisition, the LP completed a private placement offering of units for total proceeds of approximately $21.6 million. Raymond James Ltd. and Canaccord Genuity Corp. acted as co-lead agents and joint bookrunners on behalf of a syndicate of agents, which included, Richardson Wealth Limited, Wellington-Altus Financial Inc. and iA Private Wealth Inc. About Timbercreek Founded in 2000, Timbercreek is one of Canada’s leading alternative asset class investment managers, focused on debt and equity investments in high-quality, value-add commercial real estate in Canada, the United States and Europe. Through active and direct investment, Timbercreek employs a thematic approach to deliver compelling risk-adjusted returns for their investors and partners, leveraging the diversified expertise and relationships of their highly experienced team to invest capital across a wide range of asset classes. Timbercreek’s team of 50+ investment professionals have extensive domain expertise in these markets and combine an entrepreneurial growth focus with institutional risk management. Since 2000, the Timbercreek team has deployed more than $18 billion in equity and debt investments focused on value-add real estate, on behalf of their broad range of capital partners. Timbercreek has offices in Toronto, Vancouver, Montreal, New York, Dallas and Dublin. About Aspen Aspen Properties is a fully integrated and privately held boutique real estate company with over 25 years of experience in owning and managing real estate in downtown Calgary and Edmonton. Driven by an entrepreneurial spirit, Aspen is committed to creating and delivering inspiring amenity-rich real estate with innovative technology and processes that help people thrive and contribute to the development and sustainability of the communities they serve. Together with their investment partners, Aspen Properties owns and manages approximately 4.25 million square feet of office space and nearly 3,800 parking spaces in downtown Calgary and Edmonton. Aspen’s portfolio is comprised of 15 buildings—eleven in Calgary, three in Edmonton and a development site in Calgary. For more information: Timbercreek Alternatives Fraser McEwen President fmcewenf@timbercreek.com www.timbercreek.com Aspen Properties Scott Hutcheson Executive Chair of the Board rsh@aspenproperties.ca www.aspenproperties.ca

Police manhunt after 'several explosions' at regional legal office

Anthem Blue Cross Blue Shield calls off plan to cap anesthesia coverage in at least one state

WARNING: This story contains details that may distress readers. A stampede at a football match dedicated to Guinea’s junta chief killed at least 56 people, the government said on Tuesday morning (AEDT). In a shocking development following the tragedy, the opposition has accused the military-led authorities of being “directly responsible”. Spectators at Monday’s game in the country’s second-largest city of N’Zerekore invaded the pitch after one or two players were sent off and a penalty was awarded to the opposing side Labe at the end of the game, witnesses said. The events had initially been reported as clashes between fans. Officials watching the match, including two ministers, were prevented from leaving, prompting stone throwing and the firing of tear gas by security forces, a witness said, speaking on condition of anonymity. “Panic quickly set in, leading to an uncontrollable stampede,” he said. “People were trampled underfoot or injured as they tried to flee,” he added. One AFP journalist described the scenes as “mass carnage”. The match in the southeastern city was the final of a tournament organised in honour of Guinea’s junta leader, General Mamady Doumbouya, who seized power in a 2021 coup and has installed himself as president. The opposition has accused the junta of using sport for political ends. Videos circulating on social media, which AFP was unable to immediately verify, show a huge crowd packed in the dilapidated stadium. “The thousands of people at the stadium were gripped by panic and fear. It was every man for himself,” said a local official, speaking on condition of anonymity. “Protests of dissatisfaction with refereeing decisions led to stone-throwing by supporters, resulting in fatal stampedes,” the government said in a statement which was read out on national television. “Hospital services have put the provisional death toll at 56, with several others injured,” it added, describing the incident as a “tragic event”. On Monday, a doctor earlier described horrific scenes at medical facilities. “There are bodies lined up as far as the eye can see in the hospital. Others are lying on the floor in the hallways. The morgue is full,” one doctor said on condition of anonymity because he was not authorised to speak to the media. He said “there are around 100 dead”, with bodies filling the local hospital and morgue. Videos posted on social media showed chaotic scenes, with people climbing what appear to be the stadium’s perimeter walls to escape. Others showed numerous bodies lying on the ground. Doctors told AFP on Sunday that dozens had died. Access to verified information in the remote part of the West African country is limited. Local media reported that hospital wards and a morgue were overwhelmed by the injured and dead. “The government is doing everything possible to respond to this tragic event,” Doumbouya said in a statement on social media. “An emergency mission led by the prime minister has been dispatched,” he added. Doumbouya said a commission of enquiry would be set up “to rule on the causes of this tragedy and to determine who is responsible”. The junta chief called for calm in the West African nation, which has a turbulent political history and remains poor despite considerable natural resources. The crackdown on an opposition rally at a stadium in the capital Conakry left at least 156 people dead in 2009, according to a UN-mandated international commission of enquiry. Such football tournaments and other public gatherings have become common in Guinea in recent weeks, in what is widely seen as a campaign to promote Doumbouya’s candidacy in any future presidential election. The military seized power by force in September 2021 by overthrowing civilian President Alpha Conde. Under international pressure, the junta pledged to hand power back to a civilian government by the end of 2024 but has since made clear it will not. Several of Doumbouya’s aides have recently expressed their support for his possible presidential bid. One of the last remaining dissident voices in Guinea, the National Front for the Defence of the Constitution (FNDC), published a statement expressing its “outrage” at the tragedy in N’Zerekore. It said it held the junta chief and his government “directly responsible for this disaster, which cost the lives of innocent citizens, including many children”. “This demonstrates the cynical use of sport by the junta, exploiting these images of mobilisation for political ends,” the statement added. Former president Conde expressed “profound sadness and boundless outrage” in a social media post. “In a context where the country is already marked by tensions and restrictions, this tragedy highlights the dangers of irresponsible organisation and a lack of adequate preparation,” he said.Memorial planned on Dec. 11 for homeless man who died in Windsor, N.S.How to Use Gold for Retirement IncomePanic among spectators at soccer game kills at least 56 in the West African nation of Guinea